File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development

TitleThe IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development
Authors
KeywordsAITL
Isocitrate dehydrogenase
2-hydroxyglutarate
Lymphoma
T cell
Issue Date2016
Citation
Proceedings of the National Academy of Sciences of the United States of America, 2016, v. 113, n. 52, p. 15084-15089 How to Cite?
AbstractOncogenic isocitrate dehydrogenase (IDH)1 and IDH2 mutations at three hotspot arginine residues cause an enzymatic gain of function that leads to the production and accumulation of the metabolite 2-hydroxyglutarate (2HG), which contributes to the development of a number of malignancies. In the hematopoietic system, mutations in IDH1 at arginine (R) 132 and in IDH2 at R140 and R172 are commonly observed in acute myeloid leukemia, and elevated 2HG is observed in cells and serum. However, in angioimmunoblastic T-cell lymphoma (AITL), mutations are almost exclusively restricted to IDH2 R172, and levels of 2HG have not been comprehensively measured. In this study, we investigate the expression pattern of mutant IDH2 in the AITL tumor microenvironment and measure levels of 2HG in tissue and serum of AITL patients. We find that mutant IDH2 expression is restricted to the malignant T-cell component of AITL, and that 2HG is elevated in tumor tissue and serum of patients. We also investigate the differences between the three hotspot mutation sites in IDH1 and IDH2 using conditional knock-in mouse models. These studies show that in the lymphoid system, mutations in IDH2 at R172 produce high levels of 2HG compared with mutations at the other two sites and that lymphoid development is impaired in these animals. These data provide evidence that IDH2 R172 mutations may be the only variants present in AITL because of their capacity to produce significant amounts of the oncometabolite 2HG in the cell of origin of this disease.
Persistent Identifierhttp://hdl.handle.net/10722/292987
ISSN
2023 Impact Factor: 9.4
2023 SCImago Journal Rankings: 3.737
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLemonnier, François-
dc.contributor.authorCairns, Rob A.-
dc.contributor.authorInoue, Satoshi-
dc.contributor.authorLi, Wanda Y.-
dc.contributor.authorDupuy, Aurélie-
dc.contributor.authorBroutin, Sophie-
dc.contributor.authorMartin, Nadine-
dc.contributor.authorFataccioli, Virginie-
dc.contributor.authorPelletier, Romain-
dc.contributor.authorWakeham, Andrew-
dc.contributor.authorSnow, Bryan E.-
dc.contributor.authorDe Leval, Laurence-
dc.contributor.authorPujals, Anais-
dc.contributor.authorHaioun, Corinne-
dc.contributor.authorPaci, Angelo-
dc.contributor.authorTobin, Erica R.-
dc.contributor.authorNarayanaswamy, Rohini-
dc.contributor.authorYen, Katherine-
dc.contributor.authorJin, Shengfang-
dc.contributor.authorGaulard, Philippe-
dc.contributor.authorMak, Tak W.-
dc.date.accessioned2020-11-17T14:57:38Z-
dc.date.available2020-11-17T14:57:38Z-
dc.date.issued2016-
dc.identifier.citationProceedings of the National Academy of Sciences of the United States of America, 2016, v. 113, n. 52, p. 15084-15089-
dc.identifier.issn0027-8424-
dc.identifier.urihttp://hdl.handle.net/10722/292987-
dc.description.abstractOncogenic isocitrate dehydrogenase (IDH)1 and IDH2 mutations at three hotspot arginine residues cause an enzymatic gain of function that leads to the production and accumulation of the metabolite 2-hydroxyglutarate (2HG), which contributes to the development of a number of malignancies. In the hematopoietic system, mutations in IDH1 at arginine (R) 132 and in IDH2 at R140 and R172 are commonly observed in acute myeloid leukemia, and elevated 2HG is observed in cells and serum. However, in angioimmunoblastic T-cell lymphoma (AITL), mutations are almost exclusively restricted to IDH2 R172, and levels of 2HG have not been comprehensively measured. In this study, we investigate the expression pattern of mutant IDH2 in the AITL tumor microenvironment and measure levels of 2HG in tissue and serum of AITL patients. We find that mutant IDH2 expression is restricted to the malignant T-cell component of AITL, and that 2HG is elevated in tumor tissue and serum of patients. We also investigate the differences between the three hotspot mutation sites in IDH1 and IDH2 using conditional knock-in mouse models. These studies show that in the lymphoid system, mutations in IDH2 at R172 produce high levels of 2HG compared with mutations at the other two sites and that lymphoid development is impaired in these animals. These data provide evidence that IDH2 R172 mutations may be the only variants present in AITL because of their capacity to produce significant amounts of the oncometabolite 2HG in the cell of origin of this disease.-
dc.languageeng-
dc.relation.ispartofProceedings of the National Academy of Sciences of the United States of America-
dc.subjectAITL-
dc.subjectIsocitrate dehydrogenase-
dc.subject2-hydroxyglutarate-
dc.subjectLymphoma-
dc.subjectT cell-
dc.titleThe IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1073/pnas.1617929114-
dc.identifier.pmid27956631-
dc.identifier.pmcidPMC5206549-
dc.identifier.scopuseid_2-s2.0-85007490347-
dc.identifier.volume113-
dc.identifier.issue52-
dc.identifier.spage15084-
dc.identifier.epage15089-
dc.identifier.eissn1091-6490-
dc.identifier.isiWOS:000391090800055-
dc.identifier.issnl0027-8424-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats